Simplex Trading’s Taysha Gene Therapies TSHA Stock Holding History

Simplex Trading’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.9K	Sell	1,900 -3,100	-62%	-$18.3K	﹤0.01%	7478
2026 Q1	$22.3K	Sell	5,000 -6,000	-55%	-$27.9K	﹤0.01%	6688
2025 Q4	$60.5K	Buy	+11,000	New	+$53.4K	﹤0.01%	5490
2025 Q3	–	Sell	-600	Closed	-$1K	–	10106
2025 Q2	$1K	Buy	+600	New	+$1.3K	﹤0.01%	8446
2024 Q4	–	Sell	-500	Closed	-$1K	–	9659
2024 Q3	$1K	Buy	+500	New	+$1.1K	﹤0.01%	8292
2023 Q4	–	Sell	-100,100	Closed	-$316K	–	9854
2023 Q3	$316K	Buy	100,100 +89,800	+872%	+$168K	﹤0.01%	3886
2023 Q2	$6K	Buy	+10,300	New	+$7.46K	﹤0.01%	7841

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Simplex Trading's TSHA Position: Q2 2026 in Review

Simplex Trading opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 13,371 shares worth $91.1K. The stake represents ﹤0.01% of the portfolio and ranks #5670 among its holdings. This is a return to the name: Simplex Trading previously reported a position in TSHA as recently as Q4 2025.

Simplex Trading first reported a position in TSHA in Q4 2021 and has held it in 11 quarters since. The position peaked at $109K in Q4 2025. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Simplex Trading held 13,371 shares of Taysha Gene Therapies worth $91.1K as of Q2 2026.
Taysha Gene Therapies was a new Simplex Trading position in Q2 2026.
Taysha Gene Therapies made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #5670 holding.
Simplex Trading first reported a position in Taysha Gene Therapies in Q4 2021 and has held it in 11 quarters since.
Simplex Trading's Taysha Gene Therapies position peaked at $109K in Q4 2025.
209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.